The Wnt antagonist sFRP1 is downregulated in premalignant large bowel adenomas
2006

sFRP1 and Colorectal Adenomas

Sample size: 23 publication 10 minutes Evidence: moderate

Author Information

Author(s): Caldwell G M, Jones C E, Taniere P, Warrack R, Soon Y, Matthews G M, Morton D G

Primary Institution: The University of Birmingham

Hypothesis

The study investigates the relationship between sFRP1 expression and large bowel adenomas, a precursor of colorectal cancer.

Conclusion

sFRP1 expression is significantly reduced in premalignant colorectal adenomas, indicating its potential role in colorectal cancer development.

Supporting Evidence

  • sFRP1 expression was downregulated by more than 10-fold in all 12 adenomas compared with matched normal mucosa.
  • Hypermethylation of the sFRP1 promoter region was detected in all 11 adenoma samples.
  • Immunohistochemical analysis showed reduced sFRP1 protein expression in 45% of adenomas compared to normal controls.

Takeaway

This study found that a protein called sFRP1, which helps prevent cancer, is much lower in early signs of bowel cancer, suggesting it might be important for stopping cancer from developing.

Methodology

The study used real-time RT-PCR and immunohistochemistry to analyze sFRP1 expression and methylation in adenoma samples.

Potential Biases

Potential bias in sample selection as all samples were collected from patients over 50 years of age without a family history of colorectal cancer.

Limitations

The study's sample size was relatively small, which may limit the generalizability of the findings.

Participant Demographics

Patients over 50 years of age without a family history of colorectal cancer.

Statistical Information

P-Value

p<0.05

Confidence Interval

IQR 120-1500-fold

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6602967

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication